The efficacy of afamelanotide and narrowband UV-B phototherapy for repigmentation of vitiligo.

  title={The efficacy of afamelanotide and narrowband UV-B phototherapy for repigmentation of vitiligo.},
  author={P. Grimes and I. Hamzavi and M. Lebwohl and J. Ortonne and H. Lim},
  journal={JAMA dermatology},
  volume={149 1},
  • P. Grimes, I. Hamzavi, +2 authors H. Lim
  • Published 2013
  • Medicine
  • JAMA dermatology
  • BACKGROUND Vitiligo is characterized by depigmented patches of skin due to loss of cutaneous melanocytes. Many recent studies have demonstrated defects in the melanocortin system in patients with vitiligo, including decreased circulating and lesional skin levels of α-melanocyte-stimulating hormone (α-MSH). Afamelanotide is a potent and longer-lasting synthetic analogue of naturally occurring α-MSH. OBSERVATIONS We describe the preliminary results of 4 patients with generalized vitiligo who… CONTINUE READING
    70 Citations

    Figures, Tables, and Topics from this paper

    Afamelanotide for the treatment of erythropoietic protoporphyria
    • 1
    Pharmacokinetics and Pharmacodynamics of Afamelanotide and its Clinical Use in Treating Dermatologic Disorders
    • 14
    What Is New in Narrow-Band Ultraviolet-B Therapy for Vitiligo?
    • 2
    Afamelanotide (CUV1647) in dermal phototoxicity of erythropoietic protoporphyria
    • 16
    Narrowband ultraviolet B phototherapy in combination with other therapies for vitiligo: mechanisms and efficacies
    • 15
    Mechanisms and Therapeutic Prospects of Peptides in Skin Pigmentation
    • PDF


    Photo(chemo)therapy for vitiligo
    • 60
    • PDF
    Update on skin repigmentation therapies in vitiligo
    • 146
    • R. Falabella
    • Biology, Medicine
    • Indian journal of dermatology
    • 2009
    • 54
    Vitiligo: pathogenetic hypotheses and targets for current therapies.
    • 71
    Indications and action mechanisms of phototherapy.
    • T. Horio
    • Biology, Medicine
    • Journal of dermatological science
    • 2000
    • 50
    Evidence for an autoimmune pathogenesis of vitiligo.
    • 374
    The melanocortin-1 receptor is a key regulator of human cutaneous pigmentation.
    • 116
    • PDF
    Autoimmune destruction of skin melanocytes by perilesional T cells from vitiligo patients.
    • 294